Cross-sectional study finds gut barrier biomarker REG3α correlates with LDL-cholesterol in immunocompromised HIV patients, suggesting intestinal damage affects lipid metabolism in advanced disease.
Human immunodeficiency virus (HIV) infection causes gut epithelial barrier dysfunction and dyslipidemia. Intestinal fatty acid-binding protein (I-FABP) and regenerating islet-derived protein 3 alpha (REG3α) are markers of gut barrier integrity. We investigated the association between these biomarkers and LDL-cholesterol (LDL-C) in HIV-infected individuals, stratified by immune status and disease duration. This cross-sectional study included 69 HIV-infected adults on antiretroviral therapy. Plasma I-FABP, REG3α, and lipid parameters were measured. Associations were evaluated using Spearman correlation in the total cohort and stratified by cluster of differentiation 4 (CD4) count (<350, 350-500, >500 cells/μL) and disease duration (≤24, 24-48, >48 months). In the total cohort (n = 50 with lipid data), neither I-FABP (rs = -0.044, P = .762) nor REG3α (rs = 0.232, P = .105) showed a significant correlation with LDL-C. However, in patients with CD4 < 350 cells/μL (n = 12), REG3α demonstrated a strong positive correlation with LDL-C (rs = 0.643, P = .024). This association was absent in patients with higher CD4 counts (350-500: rs = 0.393, P = .383; >500: rs = 0.003, P = .985). No significant associations were observed across disease duration strata. REG3α correlates with LDL-C specifically in immunocompromised HIV patients (CD4 < 350 cells/μL), suggesting that gut barrier dysfunction may influence lipid metabolism preferentially in advanced HIV disease. This finding warrants further investigation regarding cardiovascular risk stratification in this vulnerable population.
No takes yet. Share an insight, caveat, or question.
Evik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: